17 results about "Acinetobacter infections" patented technology

The invention discloses a novel acinetobacter baumannii phage vBAbaSqsb1 and application thereof, and belongs to the technical field of microorganisms. The bacteriophage is an Acinetobacter baumannii bacteriophage vBAbaSqsb1 which is preserved in the Guangdong Microbiological Culture Collection Center on July 5, 2024, the preservation number is GDMCC (China General Microbiological Culture Collection Center) NO: 64831-B1, and the preservation address is Institute of Microbiology of Academy of Sciences of Guangdong Province. The bacteriophage can specifically recognize and split the acinetobacter baumannii so as to eliminate infection and overcome the problem of antibiotic resistance of the acinetobacter baumannii. Through discovery and application research of the phage vBAbaSqsb1, the phage vBAbaSqsb1 not only can be used for preparing a phage preparation for preventing and treating diseases caused by acinetobacter baumannii infection, but also can be used for preparing various environmental bactericides for solving potential acinetobacter baumannii in various environments. The bacteriophage vBAbaSqsb1 has the characteristics of safety, no toxic or side effect and the like, so that the problem of drug resistance caused by abuse of antibiotics can be avoided when the bacteriophage vBAbaSqsb1 is applied.

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.

The invention relates to antigen-binding proteins specifically binding Acinetobacter cells, more specifically, wherein said binding occurs through targeting a binding site of Outer membrane protein 25 (Omp25) exposed on the surface of said pathogenic Acinetobacter cells in capsulated and non- capsulated form. More specifically, the invention relates to a family of immunoglobulin single variable domains (ISVDs) capable of specifically binding the Acinetobacter baumannii Outer membrane protein 25 (Omp25) at an epitope located in the surface-exposed regions. The invention further relates to fusions of said antigen-binding proteins as multivalent, multispecific or functional fusions with further moieties, and their use in functionalized targeting of A. baumannii, as a scavenger or to induce killing activity. More particular said antigen-binding proteins or fusions are provided as a tool for detection of Acinetobacter, or for depletion of bacterial cells from a sample upon binding. Finally, the invention relates to said antigen-binding proteins for use as a diagnostic or as a medicine, preferably in prevention or treatment of Acinetobacter baumannii infection.

The invention relates to the technical field of biological pharmacy, and particularly discloses application of antibacterial small molecule peptide in preparation of antibacterial infection drugs. The antibacterial small molecule peptide is VeAMP, and the amino acid sequence of the antibacterial small molecule peptide is MKIVKRILLVL-NH2. The small molecule peptide VeAMP provided by the invention shows remarkable antibacterial activity on pan-drug-resistant acinetobacter baumannii, has the advantages of rapid sterilization, low hemolysis, low cytotoxicity and good in-vivo safety, is not easy to induce bacterial drug resistance after being exposed for a long time at a sub-inhibitory concentration, can effectively reduce tissue bacterial load, remarkably improves the survival rate of infected mice, and has a good application prospect. The invention provides a novel and safe candidate antibacterial agent which is not easy to generate drug resistance for preventing and treating drug-resistant acinetobacter baumannii infection.

The invention discloses an antibody as well as a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenem enzyme, and can reduce the carbapenem drug resistance level of the acinetobacter baumannii, so that the clinical use concentration of meropenem is reduced, and the treatment effect of meropenem on the acinetobacter baumannii is improved. In addition, the antibody disclosed by the invention can also inhibit OXA-23 protein secreted by bacteria, prevent the bacteria from hydrolyzing carbapenem antibiotics, increase the concentration of antibiotics in a medication part, and facilitate the removal of mixed infection with acinetobacter baumannii. The invention provides a new strategy for treating acinetobacter baumannii infection, and the application prospect is wide.

The invention discloses a fusion protein and application thereof. Belongs to the technical field of biological medicine. The invention provides a novel fusion molecular architecture which comprises fusion proteins coded by wza and hphA genes and can be used for research and development of nucleic acid vaccines or subunit vaccines. The invention finds that the new fusion molecule has good expression and secretion ability and immunogenicity, can provide effective immune protection effect, and significantly inhibits acinetobacter baumannii infection and colonization. The invention also provides corresponding recombinant nucleic acid, a gene expression cassette, a vector, a host cell, a pharmaceutical composition, a vaccine, application and the like.

The present application relates to the fusion protein, immunogenic composition, recombinant vaccine and application for preventing acinetobacter baumannii infection, etc. The present application screens and obtains four groups of antigen combination fusion protein mRNA vaccines of AdeK-LolB, Omp22-HphA, Omp22-LolB and CsuE-CsuAB, which show excellent effects in the mouse acinetobacter baumannii infection model. Compared with the nucleic acid vaccine encoded by the Omp22-Omp38 fusion protein known in the prior art and having excellent effects itself, the nucleic acid vaccine has better immunization effects and protective effects for preventing acinetobacter baumannii infection in reducing acinetobacter baumannii colonization and reducing the degree of lesions caused by infection, and has a wide application prospect.

The invention relates to application of naphthoquine or pharmaceutically acceptable salt in preparation of drugs for resisting drug-resistant bacteria and drugs for treating pneumonia, and the naphthoquine is an antibacterial drug for inhibiting reproduction of the drug-resistant bacteria or killing the drug-resistant bacteria. The technical problems that in the prior art, acinetobacter baumannii LAC-4 mainly generates drug resistance to sulfonamides, and the scheme for treating acinetobacter baumannii LAC-4 infection is very limited clinically are solved through the proposal of phenoquine or pharmaceutically acceptable salt.

The application discloses an antibody, a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenamase, can reduce the carbapenam antibiotic resistance level of acinetobacter baumannii, thereby reducing the use concentration of meropenem in clinic, and improving the treatment effect of meropenem on acinetobacter baumannii. In addition, the antibody can also inhibit the OXA-23 protein secreted by bacteria, prevent the hydrolysis of carbapenam antibiotics by bacteria, increase the antibiotic concentration at a drug application site, and is favorable for clearing mixed infections with acinetobacter baumannii. The application provides a new strategy for treating acinetobacter baumannii infections, and has a wide application prospect.

The invention belongs to the technical field of biology, and relates to application of a composition of caerin1.1 / 1.9, caerin1.1 / 1.9 and polymyxin B in treatment of drug-resistant acinetobacter baumannii infection. In the caerin1.1 / 1.9, the mass ratio of the caerin1.1 to the caerin1.9 is 1 to (1 to 3). In the composition, the mass ratio of the caerin1.1 / 1.9 to the polymyxin B is 1: (0.2-3). The amino acid sequences of the caerin1.9 of the caerin1.1 are as shown in SEQ ID No. 1 and SEQ ID No. 2 of the caerin1.1. The composition of the caerin1.1 / 1.9, the caerin1.1 / 1.9 and the polymyxin B plays a role in resisting carbapenem acinetobacter baumannii by reducing the biological membrane of the acinetobacter baumannii, down-regulating the expression of efflux pump genes adeA, adeB and adeC or increasing the pore number of a cell membrane.

The present invention provides a composition for inducing an immune response against Acinetobacter baumannii in a subject, comprising (i) an OXA-23 protein or (ii) a nucleic acid molecule encoding OXA- 23. The invention also provides a composition for inducing an immune response against Acinetobacter baumannii in a subject, comprising (i) a PAL protein or (ii) a nucleic acid molecule encoding PAL. The invention also provides the use of such compositions for inducing an immune response against A. baumannii and for treating A. baumannii infection.

The presently-disclosed subject matter provides a compound of Formula (I): or a pharmaceutically acceptable salt of the compound, wherein R1 is C1-4 alkyl, C1-4 alkene, or, wherein R3, R4, R5, and R6 are independently hydrogen or halogen, or R4 and R5, taken together with the atoms to which they are bound, form a 6-membered ring; and wherein X1 and X2 are independently C or N; and wherein R2 is or, wherein R7 and R8 are independently hydrogen, halogen, or C1-4 alkoxy; and the use thereof in controlling (Acinetobacter baumannii and treating A. baumannii infection.

The present application relates to a kind of naphtholquinone or pharmaceutically acceptable salt in the application of drug-resistant bacteria-resistant drug and the preparation of drug for treating pneumonia, naphtholquinone is the antibacterial drug of inhibiting drug-resistant bacteria reproduction or killing drug-resistant bacteria, by the proposal of phenol quinoline or pharmaceutically acceptable salt to solve the technical problems existing in the prior art, to solve the technical problems existing in the prior art, bauman acinetobacter LAC-4 mainly produces drug resistance to sulfonamides, in clinic, the scheme for treating bauman acinetobacter LAC-4 infection is very limited.

The invention provides an antibody for resisting acinetobacter baumannii Hcp protein or an antigen binding fragment thereof and application of the antibody or the antigen binding fragment. The invention also provides application of the antibody or the antigen binding fragment thereof in diagnosis, prevention or treatment of acinetobacter baumannii infection. The antibody or the antigen binding fragment thereof has a good application prospect.

The present invention is directed to thiourea based compounds of formula (I), as well as pharmaceutically acceptable salts or prodrugs thereof. Further the present invention provides a method for the preparation of the compounds of formula (I), pharmaceutical compositions comprising the same and their use in medicine, and preferably in the prophylaxis or treatment of Acinetobacter baumannii infections.

The application discloses application of Chembridge 53717615 in preparation of an Acinetobacter baumannii AdeABC efflux pump inhibitor, and a molecular formula of the Chembridge 53717615 is C 19 H 25 N5O2 The application discloses a method for discovering, based on computer-aided drug design, a compound Chembridge 53717615 which can inhibit the uptake and efflux of antibiotics by an Acinetobacter baumannii efflux pump and also has an inhibiting effect on the formation of a biological membrane, can greatly reduce antibiotic resistance, has important significance for treating clinical drug-resistant Acinetobacter baumannii infection, and has a great application and development prospect.